Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor

被引：0
|
作者：
Simon, T. [1 ]
机构：
[1] Univ Paris 06, AP HP, Serv Pharmacol, F-75252 Paris 05, France
来源：
ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE | 2010年 / 59卷
关键词：
Pharmacogenetics; Antiplatelet; Thienopyridine; Prognosis; Cardiovascular disease; PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; STENT THROMBOSIS; ANTIAGGREGATING ACTIVITY; CYP2C19; GENOTYPE; CLOPIDOGREL; OUTCOMES; PRASUGREL; THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Dual antiplatelet therapy with clopidogrel combined to aspirin reduces ischemic events in a wide range of patients with cardiovascular disease. However, a large interindividual variability has been observed in the pharmacodynamics response of clopidogrel with lower platelet inhibition associated with increased risk for major adverse cardiovascular events. Multiple mechanisms have been proposed for the variable response to clopidogrel, among which the impact of pharmacogenetic seems to play an important role. This article reviews the role of genetic polymorphisms in the clinical impact of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：S90 / S94
页数：5
相关论文
共 50 条
  • [41] Role of ADP receptor P2Y12 in platelet adhesion and thrombus formation in flowing blood
    Remijn, JA
    Wu, YP
    Jeninga, EH
    Ijsseldijk, MJW
    van Willigen, G
    de Groot, PG
    Sixma, JJ
    Nurden, AT
    Nurden, P
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (04) : 686 - 691
  • [42] Clash of Oral P2Y12 Receptor Inhibitors in Acute Coronary Syndromes
    Chatzizisis, Yiannis S.
    Stefanadis, Christodoulos
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (04) : 382 - 385
  • [43] The Function and Regulation of Platelet P2Y12 Receptor
    Li, Xiaohua
    Zhang, Guoxing
    Cao, Xia
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (01) : 199 - 216
  • [44] Biology and pharmacology of the platelet P2Y12 receptor
    Storey, Robert F.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (10) : 1255 - 1259
  • [45] A critical role for the ADP receptor, P2Y12, in Streptococcus oralis induced platelet activation
    Tilley, D. O.
    Maume, S. A.
    Cox, D.
    Smolenski, A.
    Douglas, C. W., I
    Kerrigan, S. W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 776 - 776
  • [46] The Function and Regulation of Platelet P2Y12 Receptor
    Xiaohua Li
    Guoxing Zhang
    Xia Cao
    Cardiovascular Drugs and Therapy, 2023, 37 : 199 - 216
  • [47] Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis
    Remijn, Jasper A.
    Ijsseldijk, Martin J. W.
    Strunk, Annuska L. M.
    Abbes, Andre P.
    Engel, Henk
    Dikkeschei, Bert
    Dompeling, Ellen C.
    de Groot, Philip G.
    Slingerland, Robbert J.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (02) : 187 - 189
  • [48] Insights into platelet P2Y12 receptor activation
    Nicholas, Robert A.
    BLOOD, 2015, 125 (06) : 893 - 895
  • [49] Identification of an inverse agonist at the ADP receptor P2Y12
    Schmidt, Philipp
    Coester, Maxi
    Simon, Kay-Uwe
    Schoeneberg, Torsten
    PURINERGIC SIGNALLING, 2012, 8 (01) : 150 - 150
  • [50] Blockade of adenosine diphosphate receptors P2Y12 and P2Y1 is required to inhibit platelet aggregation in whole blood under flow -: Response
    Turner, NA
    Moake, JL
    McIntire, LV
    BLOOD, 2002, 99 (12) : 4645 - 4646
12345